Viabilidade do uso de 1,10 fenantrolina e aptâmeros anti-MUC1 como radiossensibilizadores em células de câncer de mama

With the increase in the incidence of cancer in the Brazilian population, there is an alarming need for the study of new targeted anti-tumor therapies and therefore less toxic to the patient. The development of targeted and more effective therapeutic agents is based on the expression of specific proteins from malignant tissues, i.e., tumor markers. Following this premise, the MUC1 glycoprotein was selected as a target for experimentation of a MUC1 linker as a vector of distribution of a radiosensitizer (1.10 phenanthroline) to breast cancer cells.